Anxiety and Depression during the Second Wave of the COVID-19 Pandemic: The Role of Coping Strategies.
COVID-19 pandemic
affective symptoms
anxiety
coping strategies
depression
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
08 02 2023
08 02 2023
Historique:
received:
09
01
2023
revised:
30
01
2023
accepted:
03
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Evidence suggests increased anxious-depressive symptoms in the general population during the COVID-19 pandemic, also in its second wave. High symptom variability across individuals suggests that risk and protective factors, including coping strategies, can play a mediating role. General Anxiety Disorder-7, Patient Health Questionnaire-9, and Brief-COPE questionnaires were administered to people attending a COVID-19 point-of-care. Univariate and multivariate methods were used to test the association of symptoms with risk and protective factors. A total of 3509 participants (27.5% with moderate-severe anxiety; 12% with depressive symptoms) were recruited. Sociodemographic and lifestyle factors, including age, sex, sleep, physical activity, psychiatric treatments, parenthood, employment, and religiosity were associated with affective symptoms. Avoidant (self-distraction, venting, behavioral disengagement) and approach (emotional support, self-blame but not positive reframing and acceptance) coping strategies predicted greater anxiety. Avoidant strategies, including venting, denial, behavioral disengagement, substance use, and self-blame, and the humor strategy were associated with more severe depressive symptoms, while the planning predicted the opposite. Coping strategies, in addition to socio-demographic and life-habit factors, could have contributed to modulating anxious and depressive symptoms during the second-wave of the COVID-19 pandemic, thus advocating for interventions aimed at promoting positive coping strategies to reduce the psychosocial toll of the pandemic.
Sections du résumé
BACKGROUND
Evidence suggests increased anxious-depressive symptoms in the general population during the COVID-19 pandemic, also in its second wave. High symptom variability across individuals suggests that risk and protective factors, including coping strategies, can play a mediating role.
METHODS
General Anxiety Disorder-7, Patient Health Questionnaire-9, and Brief-COPE questionnaires were administered to people attending a COVID-19 point-of-care. Univariate and multivariate methods were used to test the association of symptoms with risk and protective factors.
RESULTS
A total of 3509 participants (27.5% with moderate-severe anxiety; 12% with depressive symptoms) were recruited. Sociodemographic and lifestyle factors, including age, sex, sleep, physical activity, psychiatric treatments, parenthood, employment, and religiosity were associated with affective symptoms. Avoidant (self-distraction, venting, behavioral disengagement) and approach (emotional support, self-blame but not positive reframing and acceptance) coping strategies predicted greater anxiety. Avoidant strategies, including venting, denial, behavioral disengagement, substance use, and self-blame, and the humor strategy were associated with more severe depressive symptoms, while the planning predicted the opposite.
CONCLUSIONS
Coping strategies, in addition to socio-demographic and life-habit factors, could have contributed to modulating anxious and depressive symptoms during the second-wave of the COVID-19 pandemic, thus advocating for interventions aimed at promoting positive coping strategies to reduce the psychosocial toll of the pandemic.
Identifiants
pubmed: 36833670
pii: ijerph20042974
doi: 10.3390/ijerph20042974
pmc: PMC9957361
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Brain Behav. 2021 Aug;11(8):e2320
pubmed: 34342152
Br J Psychiatry. 2021 Jun;218(6):334-343
pubmed: 33228822
J Affect Disord. 2022 Aug 15;311:78-83
pubmed: 35533774
J Consult Clin Psychol. 2011 Jun;79(3):342-52
pubmed: 21500885
J Affect Disord. 2022 Jul 15;309:309-313
pubmed: 35490876
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Asian J Psychiatr. 2021 Nov;65:102850
pubmed: 34534919
Int J Environ Res Public Health. 2021 Apr 20;18(8):
pubmed: 33924133
J Pain Symptom Manage. 2017 Jan;53(1):131-138
pubmed: 27725249
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Ind Psychiatry J. 2021 Jan-Jun;30(1):29-35
pubmed: 34483521
J Psychiatr Res. 2021 May;137:81-88
pubmed: 33662655
Am Psychol. 1986 Jul;41(7):813-9
pubmed: 3740641
Int J Environ Res Public Health. 2020 May 02;17(9):
pubmed: 32370116
J Occup Environ Med. 2012 Sep;54(9):1101-6
pubmed: 22929796
Int J Behav Med. 1997;4(1):92-100
pubmed: 16250744
Compr Psychiatry. 2008 May-Jun;49(3):238-46
pubmed: 18396182
J Neurosci Rural Pract. 2020 Oct;11(4):519-525
pubmed: 33144785
Stress Health. 2022 Oct;38(4):637-652
pubmed: 34902219
Int J Environ Res Public Health. 2022 Jan 31;19(3):
pubmed: 35162658
JAMA. 1999 Nov 10;282(18):1737-44
pubmed: 10568646
Curr Psychiatry Rep. 2018 Jul 23;20(8):59
pubmed: 30039327
Australas Psychiatry. 2020 Oct;28(5):514-516
pubmed: 32722963
Int J Soc Psychiatry. 2021 Aug;67(5):540-549
pubmed: 33016171
Brain Sci. 2021 Sep 17;11(9):
pubmed: 34573251
J Head Trauma Rehabil. 2019 Sep-Oct;34(5):353-363
pubmed: 31498233
Int J Environ Res Public Health. 2021 Mar 25;18(7):
pubmed: 33806163
Front Psychiatry. 2021 Feb 03;11:607246
pubmed: 33613333
Psychol Health Med. 2018 Sep;23(8):899-916
pubmed: 29533084
Asian J Psychiatr. 2021 Jul;61:102685
pubmed: 34030026
Psychiatry Res. 2020 Jun;288:112958
pubmed: 32283450
Pers Soc Psychol Rev. 2006;10(3):235-51
pubmed: 16859439
Riv Psichiatr. 2020 May-Jun;55(3):145-151
pubmed: 32489191
Singapore Med J. 2020 Jul;61(7):350-356
pubmed: 32241071
J Health Psychol. 1999 May;4(3):327-41
pubmed: 22021601
J Psychiatr Res. 2021 Aug;140:95-100
pubmed: 34102518
Psychol Psychother. 2022 Mar;95(1):98-112
pubmed: 34617396
BMC Psychiatry. 2021 Jul 13;21(1):351
pubmed: 34256718
Disaster Med Public Health Prep. 2022 Jun;16(3):920-926
pubmed: 33087206
Encephale. 2003 Nov-Dec;29(6):507-18
pubmed: 15029085
Front Psychol. 2021 Jan 25;11:601574
pubmed: 33569023
Lancet. 2020 Aug 22;396(10250):565-582
pubmed: 32828189
Brain Behav. 2021 Jan;11(1):e01938
pubmed: 33174360
Psychol Bull. 2003 Mar;129(2):216-269
pubmed: 12696840
J Nerv Ment Dis. 2008 Nov;196(11):838-43
pubmed: 19008735
Front Public Health. 2021 Jul 08;9:655083
pubmed: 34307274
Ann Gen Psychiatry. 2021 May 24;20(1):31
pubmed: 34030704
Depress Res Treat. 2020 Aug 26;2020:3158954
pubmed: 32908697
J Neurol. 2021 Jan;268(1):8-15
pubmed: 32654065
J Clin Psychol. 2000 Apr;56(4):519-43
pubmed: 10775045
Indian J Psychol Med. 2020 Oct 13;42(6):575-576
pubmed: 33354086
Sports Med. 2021 Aug;51(8):1771-1783
pubmed: 33886101
Psychiatry Res. 2020 Sep;291:113251
pubmed: 32593071
Front Psychol. 2021 Mar 30;12:639955
pubmed: 33859594
J Affect Disord. 2022 Mar 1;300:563-570
pubmed: 34965402
Front Psychol. 2021 May 21;12:648069
pubmed: 34093332
Psycholog Relig Spiritual. 2016 Feb 1;8(1):46-53
pubmed: 27019677
Gac Med Mex. 2020;156(4):298-305
pubmed: 32831341
BMC Psychiatry. 2021 Jan 8;21(1):20
pubmed: 33419391
J Am Coll Health. 2022 Apr;70(3):679-690
pubmed: 33651672
Psychol Res Behav Manag. 2021 Jun 18;14:795-804
pubmed: 34177277
Pers Individ Dif. 2021 Jun;175:110691
pubmed: 33518867
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110207
pubmed: 33338558
JAMA Netw Open. 2020 Jul 1;3(7):e2014053
pubmed: 32609353